Want to see AU:ATX full AI Analyst Report?
ATX Stock Chart & Stats
AU$0.14
-AU$0.01(-7.14%)
At close: 4:00 PM EDT
AU$0.14
-AU$0.01(-7.14%)
Day’s Range― - ―
52-Week RangeAU$0.10 - AU$0.28
Previous CloseN/A
Volume422.49K
Average Volume (3M)1.29M
Market Cap
AU$66.73M
Enterprise ValueAU$93.06
Total Cash (Recent Filing)AU$27.85M
Total Debt (Recent Filing)AU$341.11K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding513,312,000
10 Day Avg. Volume927,565
30 Day Avg. Volume1,294,715
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-12.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.42Price Target Upside200.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Equity CushionEquity representing most of the asset base provides a meaningful financial cushion while the company funds clinical development. This reduces balance-sheet fragility and may give management more flexibility to sustain operations and pursue its oncology program.
Low LeverageLow debt limits fixed financial obligations and interest-related pressure, which is valuable for a clinical-stage biotechnology company without dependable commercial revenue. A lightly leveraged balance sheet can preserve strategic flexibility as development milestones progress.
Focused Oncology PlatformA concentrated development strategy around FAK biology and a lead oncology candidate can focus scarce resources, scientific expertise, and capital on a defined therapeutic thesis. Progress in the lead program could therefore have material strategic importance.
Bears Say
Revenue Collapsed To ZeroThe move to zero revenue shows that the company currently lacks a dependable operating revenue stream to support its cost base. This leaves financial progress heavily dependent on advancing development programs and securing future commercial or funding outcomes.
Persistent, Widening LossesRecurring and generally widening losses indicate that the business has not yet reached economic sustainability. Continued deficits can erode the equity cushion over time and make future progress dependent on successful clinical development and disciplined spending.
Worsening Cash BurnIncreasing operating cash outflows and consistently negative free cash flow show that the company continues consuming capital to operate. Unless cash generation improves, ongoing development and corporate activities may require additional financial resources.
Amplia Therapeutics News
ATX FAQ
What was Amplia Therapeutics Ltd.’s price range in the past 12 months?
Amplia Therapeutics Ltd. lowest share price was AU$0.10 and its highest was AU$0.28 in the past 12 months.
What is Amplia Therapeutics Ltd.’s market cap?
Amplia Therapeutics Ltd.’s market cap is AU$66.73M.
When is Amplia Therapeutics Ltd.’s upcoming earnings report date?
Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 78 days.
How were Amplia Therapeutics Ltd.’s earnings last quarter?
Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter.
Is Amplia Therapeutics Ltd. overvalued?
According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Undervalued.
Does Amplia Therapeutics Ltd. pay dividends?
Amplia Therapeutics Ltd. does not currently pay dividends.
What is Amplia Therapeutics Ltd.’s EPS estimate?
Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Amplia Therapeutics Ltd. have?
Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.
What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?
Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amplia Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.42 (200.00% Upside)
AU$0.42 (200.00% Upside)
Blogger Sentiment
Bullish
AU:ATX Sentiment 96%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.19%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
98.58%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Amplia Therapeutics Ltd.
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
ATX Stock 12 Month Forecast
Average Price Target
AU$0.42
▲(200.00% Upside)
Technical Analysis
Tryptamine Therapeutics
―
Neuren Pharmaceuticals Limited
―
Paradigm Biopharmaceuticals
―
Alterity Therapeutics
―
Zelira Therapeutics
―